Literature DB >> 1531407

Is tinea unguium still widely incurable? A review three decades after the introduction of griseofulvin.

H C Korting1, M Schäfer-Korting.   

Abstract

BACKGROUND: Tinea unguium, especially of the feet, for ages has been looked on as an incurable disease. Today, therapeutic outcome is still controversial. To evaluate the present state of antifungal therapy of dermatophytoses of the nails, a survey of the pertinent literature has been performed. OBSERVATIONS: The introduction of griseofulvin three decades ago was first considered a major breakthrough. Today, however, conventional griseofulvin treatment regimens must be called disappointing in terms of clinical and microbiological cure to be achieved. Cure rates of 40% to 100% have been reported for fingernail infections, but only 3% to 38% for toenail tinea. Microbiological cure rates look only slightly better. Limited experience suggests that additional measures such as surgical nail avulsion or topical antifungal treatment might improve therapeutic outcome. Toenail avulsion increases cure rates to 47% to 82%. The lack of an adequate follow up, however, makes all statements questionable.
CONCLUSIONS: Results are only limited with respect to newly developed oral antifungal agents. Whereas ketoconazole treatment had to be omitted due to its hepatotoxic effect, its congener, intraconazole, is under investigation. High cure rates have been obtained in a preliminary study with oral terbinafine, 0.25 g/d, for 12 months, which have cleared toenail tinea in 15 of 17 patients. The value of topical treatment alone has not yet been definitely established. The application of a topical azole (bifonazole) in combination with chemical nail avulsion, using urea paste under occlusion, has resulted in negative cultures in 62% of the patients 3 months after the end of treatment.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1531407

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  14 in total

Review 1.  An overview of topical antifungal therapy in dermatomycoses. A North American perspective.

Authors:  A K Gupta; T R Einarson; R C Summerbell; N H Shear
Journal:  Drugs       Date:  1998-05       Impact factor: 9.546

Review 2.  A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis.

Authors:  A K Gupta; N H Shear
Journal:  Drug Saf       Date:  2000-01       Impact factor: 5.606

Review 3.  Terbinafine. A pharmacoeconomic evaluation of its use in superficial fungal infections.

Authors:  R Davis; J A Balfour
Journal:  Pharmacoeconomics       Date:  1995-09       Impact factor: 4.981

4.  Results of German multicenter study of antimicrobial susceptibilities of Trichophyton rubrum and Trichophyton mentagrophytes strains causing tinea unguium. German Collaborative Dermatophyte Drug Susceptibility Study Group.

Authors:  H C Korting; M Ollert; D Abeck
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

5.  Therapeutic efficacy of topically applied KP-103 against experimental tinea unguium in guinea pigs in comparison with amorolfine and terbinafine.

Authors:  Yoshiyuki Tatsumi; Mamoru Yokoo; Hisato Senda; Kazuaki Kakehi
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

6.  Modes of action of the new arylguanidine abafungin beyond interference with ergosterol biosynthesis and in vitro activity against medically important fungi.

Authors:  C Borelli; M Schaller; M Niewerth; K Nocker; B Baasner; D Berg; R Tiemann; K Tietjen; B Fugmann; S Lang-Fugmann; H C Korting
Journal:  Chemotherapy       Date:  2008-06-30       Impact factor: 2.544

7.  Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole.

Authors:  H C Korting; M Schäfer-Korting; H Zienicke; A Georgii; M W Ollert
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

8.  Influence of serum protein binding on the in vitro activity of anti-fungal agents.

Authors:  M Schäfer-Korting; H C Korting; W Rittler; W Obermüller
Journal:  Infection       Date:  1995 Sep-Oct       Impact factor: 3.553

Review 9.  Common fungal infections of the feet in patients with diabetes mellitus.

Authors:  James S Tan; Warren S Joseph
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 10.  Pharmacokinetic optimisation of oral antifungal therapy.

Authors:  M Schäfer-Korting
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.